Immune privilege
A range of mechanisms exist to limit immune responses in the CNS; indeed, the CNS is considered to be an immune-privileged site. As early as 1921, it was shown that rat sarcoma cells grow well in mouse brain parenchyma but not when transplanted under the skin or into muscle (1). For decades thereafter, it was assumed that the CNS and retina enjoy immune privilege because they are hidden behind the blood-brain barrier (BBB), blood-cerebrospinal fluid barrier (BCSFB), or the blood-retinal barrier (BRB) (Figure 1). However, the view that the CNS is completely ignored by the immune system has turned out to be overly simplistic. This is in part because immune privilege is relative rather than absolute; the immune response to nontumor foreign tissue in the CNS is delayed rather than prevented (2). This delay is related to several factors — the CNS lacks conventional lymphoid drainage (3) and CNS-derived antigen may be transported to cervical lymph nodes in the fluid phase (4) or associated with DCs following tissue trauma (5). The parenchyma of the normal brain and spinal cord has a limited capacity for antigen processing and presentation, since it contains few professional APCs and neurons only express MHC under exceptional conditions (6). The effector arm of the immune response is also hindered, since lymphocytes have to be activated before they can cross the BBB or BRB (7, 8), and even then this transmigration process is challenging. Once in CNS tissue, the environment remains inherently hostile to activated lymphocytes expressing FAS, ligation of which by FAS ligand (FASL), expressed on all cells in the CNS, results in death by apoptosis (9, 10). Microglia, the innate immune cells of the CNS, further respond to inflammation by upregulation of immunoregulatory molecules including B7-H1 (11) and IDO (12), while neurons protect themselves by secreting TGF-β upon contact with activated lymphocytes (13). FAS and TGF-β have also been implicated in the suppression of immune responses in the eye (refs. 14, 15, and Figure 2).

Immune surveillance
The nature and origin of APCs in the CNS is only now becoming clear. Resident brain microglial cells are derived from primitive myeloid progenitors that differentiate in the yolk sac (16), although bone marrow-derived cells may reconstitute the CNS following trauma (17). Greter and colleagues have shown that immune responses in the CNS depend on CD11c+ cells found in the juxtavascular parenchyma, with cell processes extending into the glia limitans (18). Importantly, these cells may be blood born or alternatively derive from an intraparenchymal, microglial precur- sor stimulated with GM-CSF (19). Cells sharing the properties of conventional DCs have recently been found in the meninges and choroid plexus of healthy mouse brain (20). These cells are derived from bone marrow pre-DC progenitors and share morphological characteristics, gene expression patterns, and the ability to present antigen with splenic DCs (20). Apart from these populations of DCs, the CNS parenchyma is relatively devoid of APCs. This all changes, however, in the inflamed CNS or retina when myeloid (CD11b+) DCs flood into the site, amplify the immune response, and promote epitope spreading (21–23).

The non-inflamed brain and retina are protected by vascular endothelium at the BBB and BRB, while epithelial cells of the choroid plexus form the BCSFB (Figure 3). Furthermore, astrocytic end feet and the parenchymal basement membrane form a further barrier, the glia limitans. Nevertheless, CSF from individuals with no inflammatory neurological disease contains about 150,000 T lymphocytes (24). These cells circulate through the CSF for approximately six hours before returning to the circulation (24) — a low rate of cell traffic when compared with peripheral lymphocyte recirculation (25). The T cells in human CSF are mainly effector memory (CD45RA−, CD27+, L-selectin+) and the majority are CD4 positive (26). This phenotype permits trafficking through extra-lymphoid tissue as well as subsequent return to the lymphatic system via high-endothelial venules. Activated lymphocytes make formal contact with the BBB via α4-integrin and endothelial VCAM-1 (27) and cross the barrier by diapedesis. This is a difficult process, especially in the non-inflamed CNS, although entry to the leptomeningeal compartment can occur more readily in a P-selectin-dependent manner (28). Even then, entry to the CNS parenchyma is dependent on further encounter with cognate antigen. If antigen is seen, then the immune cells mount an inflammatory response, draw other immune cells into the specific site, and then collectively breach the glia limitans to infiltrate the parenchyma.

Conflict of interest: David C. Wraith has a financial interest in Aptepic, which is developing antigen specific therapies for autoimmune diseases.

Citation for this article: J Clin Invest. 2012;122(4):1172–1179. doi:10.1172/JCI58648.
Lymphocyte migration into and within the CNS is regulated by chemokines and their receptors. Without concomitant inflammation, CD4⁺ migration outside of blood vessels is constrained to pathways that run along their axes (29) and is different from the random motility of CD8⁺ cells (29–31). This confinement is regulated by the interaction of the chemokine CXCL12 with the receptor CXCR4, expressed on the surface of lymphocytes. The migration of leukocytes into the CNS may be modulated by sequestration of CXCL12 by other receptors (32), or by the physical redistribution of CXCL12 that occurs in MS and the disease model EAE (30, 31). In addition, blockade of CXCR4 allows CD4 T cells to escape from their perivascular containment and penetrate deeper into brain parenchyma (29, 30). Collectively these mechanisms ensure that immunosurveillance within the normal CNS occurs at a slower pace than in the periphery and is biased to recently activated CD4⁺ cells with a phenotype that allows them to traffic back to secondary lymphoid tissue once they leave the nervous system. However, immunosurveillance of the CNS is a critical mechanism, as illustrated recently by the observation of complications associated with antibody therapies for MS that block this process. Treatment with natalizumab, an anti-α4-integrin, increases the risk of progressive multifocal leukoencephalopathy (PML) caused by the John Cunningham (JC) Virus (33). This is virtually never seen in immune-competent individuals (34), attesting to the effectiveness of the immune surveillance of CNS tissue.

CNS disease associated with infection

Infections of the CNS frequently cause devastating disease with long-term neurological sequelae. It is also appreciated that the tissue damage caused by such fulminant inflammatory responses in the brain may have more severe consequences than the infection itself. However, life-threatening inflammation is not the only manifestation of immune responses within the CNS, and certain viral infections of the CNS and meninges can produce transient symptoms that resolve completely. Studying adaptive immune responses within immunoprivileged sites that can resolve without clinical sequelae is challenging, especially in humans. In the retina, such events manifest as multiple evanescent white dot syndrome, putative immune granulomas often of unknown cause that have a spectrum of clinical outcomes from resolution to chronic disease (35). Other examples of clinically silent pathology include aseptic meningitis, most commonly caused by enteroviruses, in which the infection is cleared from the tissue, and infection followed by latency as caused by herpes viruses. In this latter case, immunosuppression can promote reactivation of the virus — for example, in patients receiving treatment with antibodies that deplete peripheral lymphocytes (36), which can lead to acute retinal pathology (37). The precise origin of the reactivation is difficult to determine, but in animal models, latent virus can be detected in the trigeminal ganglion and hypothalamus (38). Together this evidence demonstrates that the CNS can support effective adaptive immune responses while preserving normal function.

Infectious agents may cause neurological disease by a direct lytic effect, exemplified by Venezuelan equine encephalitis virus in children and West Nile virus in older adults (39). Alternatively, damage can be caused by the immune response to the virus-infected cells; examples of viruses causing immunopathology in the CNS include Eastern equine encephalitis virus in humans and Sindbis virus in mice (40). Human T-lymphotrophic virus type 1

**Figure 1**

Physical barriers protecting the brain. The brain is the most highly protected organ in the body. It is protected from physical insult by the skull and associated tissues. The BBB provides protection from pathogens in the blood and from the cells and antibodies of the immune system. The BBB is more effective than other vascular-tissue barriers because the endothelial cells form tight junctions of high electrical resistance that limit transcellular movement of molecules. The glia limitans, formed from parenchymal basement membrane and astrocytic foot processes, forms a further barrier between blood and neuronal tissue.
(HTLV-1) infection may result in HTLV-associated myelopathy (HAM), also known as tropical spastic paraparesis (TSP), but this must occur by a different, indirect mechanism. HTLV-1 infects both CD4 and CD8 lymphocytes and causes T cell leukemia/lymphoma among CD4 cells (41). Interestingly, however, there is little or no HTLV-1 infection of CNS cells in HAM/TSP (42), and risk of developing HAM/TSP correlates most strongly with the proportion of peripheral blood mononuclear cells carrying integrated HTLV-1 provirus. In contrast, a strong CD8 antiviral response reduces proviral load and hence reduces the risk of HAM/TSP (43). A poor CD8 response to the virus results in a high number of infected and activated CD4 T cells, and a high percentage of these cells is able to enter the CNS, where they form an immune battleground between the infected cells and HTLV-1-specific lymphocytes. The latter secrete inflammatory cytokines and metalloproteinases, and these cause tissue damage in a bystander fashion.

A further mechanism of neuronal disease associated with infection is revealed through studies of Sydenham chorea. This disorder may occur months after group A streptococcal infection and is associated with antibodies against basal ganglia (44). Monoclonal antibodies from patients with Sydenham chorea were shown to react with intracellular tubulin, extracellular lysoganglioside GM1, and the GlcNAc epitope of streptococcal group A carbohydrate, consistent with a mechanism of molecular mimicry (45). Antibodies from Sydenham chorea patients react strongly with cytoplasmic antigens in human caudate and subthalamic nuclei as well as cerebral cortex neurons (44). These antibodies are specific to patients with symptoms of chorea and are not seen in rheumatic heart disease, and their levels correlate with severity and duration of choreic symptoms. Whether or not anti-tubulin or anti-lysoganglioside antibodies cause the pathology remains unclear. Some antibodies against lysoganglioside have, however, been shown to activate calcium/calmodulin-dependent protein kinase II in human neuronal cells (46).

One question that arises is how such cross-reactive antibodies cross the BBB or BCSFB in the first place. Evidence from a study of systemic lupus erythematosus (SLE) has shown that anti-dsDNA antibodies can cross-react with NMDA receptor on the cell surface and induce apoptosis of neurons in the hippocampus and lateral amygdala (47). Importantly, in this study Huerta and colleagues showed that the BBB had first to be disrupted for these antibodies to cause pathology. The phenomena of molecular mimicry and the induction of cross-reactive antibodies are probably more common than we appreciate. The integrity of the BBB and BCSFB means, however, that this rarely manifests as a clinical feature of either the infection or autoimmune condition. In summary, infectious agents may cause neurological disease through a direct lytic effect, by inducing immunopathology directed against CNS tissue, by induction of immune responses that damage CNS tissue in a bystander fashion, or through induction of molecular mimicry.

The control of virus infection and survival of the host, especially in response to viruses adapted to evade the immune system, may require the production of antibodies within the CNS and/or the generation of protective but non-lytic effector functions. For example, coronavirus infection of mice results in acute encephalomyelitis followed by persistent infection (48). Serum antibody levels correlate with levels of tissue antibody-secreting cells in the periphery and decline following viral clearance. However, antibody-secreting cells persist in the CNS consistent with intrathecal antibody synthesis. The CNS is therefore able to support antibody-secreting cells even after resolution of virus infection. Evidence for long-term persistence of CD103+ pathogen-specific memory CD8+ cells in the CNS comes from elegant work using vesicular stomatitis virus (49). Furthermore, human tissue studies have identified CD8+ cells associated with trigeminal ganglia infected with herpes simplex virus (50). Although granzyme B was expressed by these cells, they appeared to be non-cytolytic. Similar findings have been described in animal models of herpesvirus infection, in which both granzyme- and cytokine-dependent effector mechanisms are important for
A syndrome is unequivocally linked to antibodies that interfere with receptor signaling (53). Furthermore, stiff person syndrome is unequivocally linked to antibodies that interfere with the GABA-receptor pathway (GAD65, amphiphysin, GABARAP); as yet, however, which of these antibodies results in pathology is less clear (52). The same is true for antibodies associated with other movement disorders, especially those specific for cytoplasmic antigens, in which the pathogenic link remains obscure. In many cases, paraneoplastic movement disorders are successfully treated by removal of the tumor with or without additional immune suppression.

Autoimmune diseases of the CNS
Autoimmune diseases are characterized by strong association with genes, usually class II, in the MHC (54); weak association with a range of other genes encoding proteins known to regulate immune responses (55); lymphocyte infiltration of the affected tissue (56); raised levels of class-switched autoantibodies in serum or the affected tissue (57); higher frequency of activated or memory lymphocytes (CD45RO+ T cells in humans) specific for self-antigens (58); and the suppression of disease progression through treatment with strong immune-suppressive drugs (59). Autoimmune diseases that affect the CNS include MS and neuromyelitis optica (NMO).

Until recently, NMO, or Devic’s disease, was considered to be a form of MS, since the immune system targets myelin in both diseases (60). Pathogenic lesions in MS are found in both brain and spinal cord, whereas the autoimmune attack in NMO specifically affects the spinal cord and optic nerve; hence, the symptoms of NMO are loss of vision and spinal cord function. Definite diagnosis of NMO is based on evidence of optic neuritis, acute myelitis, and at least 2 of the following additional criteria: (a) contiguous spinal cord MRI lesions over 3 vertebral segments, (b) brain MRI not meeting criteria for MS, and (c) presence of antibodies against aquaporin-4, a highly specific marker of NMO (61). These antibodies are detectable in at least 80% of patients with NMO and have been shown to cause relevant pathology when either transferred directly into the CNS of mice (62) or injected into animals with EAE that have a disrupted BBB (63), allowing free passage of IgG antibodies into the brain. There is also evidence for increased T-cell immunity against aquaporin-4 in NMO (64). Importantly, MS is more common in populations of mixed European descent, whereas NMO is relatively more frequent in individuals not of mixed European descent, implying a strong genetic contribution to susceptibility. In MS there is a clear association with the HLA-DRB1*1501 allele in populations of European origin, while HLA-DRB1*0301 and DRB1*0405 are more common in Sardinia (65); these alleles of the MHC class II HLA-DR locus constitute the strongest genetic association with MS (66). Similarly, NMO is associated with HLA class II, and it appears, from the few small studies conducted, that the associated allele depends on ethnicity. That is, NMO has been associated with HLA-DP*0301 and DRB1*0405 are more common in Japan (67), whereas patients in France (68) and Brazil (69) expressing the anti-aquaporin antibody are likely to be HLA-DRB1*03. Therefore, NMO is an autoimmune disease of the CNS that shares some of the features with MS but is distinct both genetically and in immunopathology. Narcolepsy fulfills some, but not all, of the features of an autoimmune disease. This disabling CNS disorder causes daytime sleepiness and sleep attacks that develop because of a deficiency of hypocretin-producing neurons in the hypothalamus (70). The majority of patients with narcolepsy carry the HLA DRB1*0102 allele (71). Recent studies have also revealed disease-associated polymorphisms in genes encoding the TCR α-chain (72), TNF-α (73)
and the TNF receptor II (74). Despite such tantalizing immunogenetic evidence, there is insufficient definitive proof that narcolepsy is an autoimmune condition. Oligoclonal bands are not seen in the CSF (75), nor are there signs of inflammation in the hypothalamus in postmortem studies (76, 77). As discussed above, neurological disturbance can result from various mechanisms, ranging from direct immune attack, bystander activation, or molecular mimicry. It remains possible that a subtle, local bystander activation mechanism, distinct from the type of pathology seen in MS and NMO, could account for the specific depletion of hypothalamic neurons producing hypocretin peptides, but this awaits further investigation.

The available therapies for many autoimmune diseases are not curative and are often associated with unacceptable side effects. Over the past 20 years, advances in our understanding of the immune pathology of autoimmune diseases have led to new treatments that offer significant advantages over previous therapies. This is well illustrated in the case of MS, for which various treatment approaches have recently entered clinical trials or have been added to the armamentarium of the neurologist (Figure 4). Interferon-β was introduced in the 1980s, in the belief that MS was caused by an unknown virus, and was shown to suppress inflammation in some but not all patients. Recently, Axtell and colleagues provided insight into why the effects of interferon-β may vary (78). In the mouse EAE model, interferon-β was shown to suppress disease caused by myelin-specific Th1 cells but to exacerbate Th17-associated disease. Interestingly, patients who do not respond to treatment with interferon-β have constitutively high levels of IL-17F (78). Extrapolating these findings to the general population of patients with MS, one could speculate that the efficacy of interferon-β in a given individual might depend on the balance of Th1 and Th17 cells causing pathology. Relative cytokine production by peripheral blood cells in response to myelin antigens could be used to stratify patients and thereby improve the effective treatment of MS with interferon-β.

There is now no doubt that MS is an autoimmune disease associated with the adaptive immune response to myelin antigens. Most strikingly, patients with relapsing MS have shown an impressive reduction in disability at 6 months after treatment with the CD52-targeting monoclonal antibody alemtuzumab (Campath 1H) (79). This antibody has a profound and long-lasting effect on the CD4 lymphocyte count, and this alone implicates CD4 T cells as key in controlling the pathogenesis of MS. Treatment with rituximab, an antibody targeting the CD20 molecule on B cells and leading to

---

**Table 1** Examples of paraneoplastic movement disorders

<table>
<thead>
<tr>
<th>Disease</th>
<th>Related tumor</th>
<th>Antibody target</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chorea</td>
<td>SCLC and thymoma</td>
<td>CRMP-5</td>
<td>94</td>
</tr>
<tr>
<td>NMDA receptor encephalitis</td>
<td>Teratoma (in women)</td>
<td>NMDAR (NR1)</td>
<td>95</td>
</tr>
<tr>
<td>Brainstem encephalitis</td>
<td>Testis (in men under 50 years of age), solid tumor (in men over 50), lymphoma (in women)</td>
<td>MA2</td>
<td>96</td>
</tr>
<tr>
<td>Cerebellar degeneration</td>
<td>Breast, ovary, Hodgkin’s lymphoma</td>
<td>Yo</td>
<td>97</td>
</tr>
<tr>
<td>Stiff person syndrome</td>
<td>SCLC, breast</td>
<td>TR</td>
<td>98</td>
</tr>
<tr>
<td>Opsoclonus-myoclonus</td>
<td>Neuroblastoma (in children); SCLC, breast, ovarian (in adults)</td>
<td>VGCC</td>
<td>99</td>
</tr>
</tbody>
</table>

---

![Figure 4](http://www.jci.org)

**Figure 4**

Current and future therapies for MS. The holy grail for treatment of autoimmune disease is to design a drug that will selectively target the cells causing the disease, avoid nonspecific immune suppression, and have minimal adverse effects. Increasingly specific approaches target the adaptive immune response to antigens in the CNS. Examples of these include antilymphocyte drugs (alemtuzumab), anti–T cell drugs (daclizumab), drugs targeting lymphocyte migration (natalizumab and fingolimod), APL (GA), and the target antigen (myelin peptides or DNA vaccine).
B cell depletion, has also been shown to lower the burden of brain lesions in MS and significantly reduce relapses (80). This may suggest a previously underappreciated role for autoantibodies in immune pathology, or alternatively an important role for B cells in the presentation of antigen to pathogenic CD4 T cells. Work in the EAE model previously revealed the role of VLA-4 as the integrin involved in lymphocyte traffic into the CNS; the anti–VLA-4 antibody HP2/1 prevented onset of EAE in the Lewis rat model (27). Natalizumab, the human equivalent of HP2/1, has been highly effective in reducing inflammatory lesions in MS. Clinical trials have, however, revealed an increased susceptibility to PML in patients treated with natalizumab (81). PML is caused by the reactivation of the JC Virus polyomavirus in the CNS of immune-compromised individuals (82). Similar viral complications may also arise upon treatment with fingolimod (Gilenya), a sphingosine-1 phosphatase (S1P) receptor modulator. S1P signaling is required for lymphocytes to egress from lymph nodes. Hence, treatment with fingolimod prevents lymphocytes leaving the lymph nodes and entering the CNS. In a recent trial, fingolimod significantly lowered relapse rate in relapsing-remitting MS (83). However, two fatal viral infections, disseminated varicella and herpes simplex encephalitis, occurred among 369 patients treated at the higher dose of the drug (83). Clearly, further analysis of dose and duration of treatment will be required to assess the long-term safety of drugs that modulate lymphocyte migration.

An antigen-specific “tolerogenic” approach specifically targeting the TCRs of pathogenic cells is considered the holy grail for immunotherapy (84). Altered peptide ligands (APLs) are variants of T cell epitopes designed to alter the response of T cells by inducing apoptosis, anergy, or modulation of cytokine secretion (85). The prototypic APL for treatment of autoimmune disease is copolymer 1, also known as copaxone or glatiramer acetate (GA) (86). GA is thought to work by modulating myelin basic protein–specific (MBP-specific) T cells toward a Th2/anti-inflammatory phenotype (87) or, alternatively, by upregulating IL-10 secretion by CD8 cells (88). APL more specifically targeting the TCRs of myelin-specific cells have been designed and tested in clinical trials. High doses of APL, based on MBP peptide 83–99, caused allergic complications when injected subcutaneously (89) and may have led to disease exacerbation in some patients (90). It was previously shown that an antagonist for one TCR may function as an agonist for the next (91); this impugns the advantage of using APL over the native sequence. Since the early studies with APL, antigen-specific therapies based on peptides and DNA vaccines have been developed. High-dose treatment with MBP peptide 82–98 led to a reduction in anti-MBP antibodies and delayed disease progression in the HLA-DR2/DR4 subgroup of patients (92). A DNA vaccine encoding MBP, with CpG motifs replaced by GpG, was recently tested in MS patients (93). Treatment with a 0.5-mg dose of DNA resulted in the reduction of new lesions in the CNS, coinciding with a decrease in the Th1 response to myelin antigens. Whether antigen-specific therapy will be sufficiently powerful to reduce progression of disease cannot be determined without further testing. One can envision a situation in which disease is treated by short-term dosage with a strong, nonspecific immune suppressant, with disease suppression being maintained in the long term with a safer, antigen-specific approach.

Conclusion
In summary, the CNS has co-evolved a close relationship with the immune system that allows a sophisticated and nuanced manifestation of the normal inflammatory process (Figure 5). An ongoing immune response within the immune-privileged tissue modifies its immunosurveillance, and this is characterized by changes in the immune cell content of the target organ. Such changes can be successful in controlling local pathology while preserving function but may alter the risk of CNS sequelae following peripheral immune activation.

Acknowledgments
D.C. Wraith acknowledges financial support from the Wellcome Trust & MS Society UK. L.B. Nicholson acknowledges support from the National Eye Research Centre & MS Society UK.

Address correspondence to: David C. Wraith, Department of Pathology and Microbiology, University of Bristol, University Walk, Bristol BS8 1TD, United Kingdom. Phone: 44.117.928.7983; Fax: 44.117.928.7896; E-mail: D.C.Wraith@bristol.ac.uk.
1. Shirai Y. On the transplantation of the rat sarco-

2. Galea I, Bechmann I, Perry VH. What is immune privi-

3. Weller RO, Galea I, Carrazzo RO, Minagar A. Patho-
physiology of the lymphatic drainage of the cen-


8. Galea I, Bechmann I, Perry VH. What is immune privi-


